Company Renovaro Inc.

Equities

RENB

US29350E1047

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
2.02 ^USD	-6.05%		-16.53%	-36.28%

Apr. 18	Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board	CI
Mar. 13	Renovaro Inc. Appoints Simon Tarsh as Interim Chief Financial Officer	CI

Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

Number of employees: 12

Managers	Title	Age	Since
Mark Dybul CEO	Chief Executive Officer	60	18-01-22
Lester Russell CTO	Chief Tech/Sci/R&D Officer	-	23-08-20
Greg Duczynski CTO	Chief Tech/Sci/R&D Officer	-	15-12-31
Joseph R. Cohen CTO	Chief Tech/Sci/R&D Officer	-	-
François Binette COO	Chief Operating Officer	-	22-04-19

Members of the board	Title	Age	Since
Gregg Alton BRD	Director/Board Member	58	19-12-31
Avram Miller BRD	Director/Board Member	-	23-10-10
James Sapirstein BRD	Director/Board Member	62	18-03-05
Leni M. T. Boeren BRD	Director/Board Member	60	23-10-03
Rudolphus Gabriel Cornelis Hendriks BRD	Director/Board Member	78	23-10-03
Carol Brosgart BRD	Director/Board Member	72	19-12-26
Rene Sindlev CHM	Chairman	61	11-01-17
Mark Dybul CEO	Chief Executive Officer	60	18-01-22
Jayne McNicol BRD	Director/Board Member	57	21-05-24

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	143,668,372	105,978,359 ( 73.77 %)	0	73.77 %
Stock B	0	561,010	0	0

Name	Equities	%	Valuation
Rs Group ApS 9.470 %	13,605,297	9.470 %	36 M $
Serhat Gumrukcu 8.658 %	12,438,431	8.658 %	33 M $
Ole Abildgaard 5.501 %	7,903,482	5.501 %	21 M $
William Anderson Wittekind 3.623 %	5,204,446	3.623 %	14 M $
Weird Science LLC 0.9143 %	1,313,499	0.9143 %	3 M $
Avram Miller 0.6960 %	1,000,000	0.6960 %	3 M $
Vanguard Global Advisers LLC 0.2715 %	390,107	0.2715 %	1 M $
Morgan Stanley Capital Services LLC 0.2526 %	362,978	0.2526 %	961 892 $
Geode Capital Management LLC 0.2523 %	362,409	0.2523 %	960 384 $
BlackRock Institutional Trust Co. NA 0.1961 %	281,672	0.1961 %	746 431 $

Name	Equities	%	Valuation
Ole Abildgaard 61.25 %	343,619	61.25 %	910 590 $

Renovaro, Inc.

1927 Paseo Rancho Castillo

90032-2012, Los Angeles

+45 39 17 98 40

http://www.enochianbio.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
RENOVARO INC.	-36.28%	290M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+2.39%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-6.82%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs